openPR Logo
Press release

Latest Guidebook for Review and Approval Procedures of Overseas Imported New Drugs for Chinese Clinical Urgent Demand (2019 Edition)

05-28-2019 09:20 AM CET | Health & Medicine

Press release from: Valuates Reports

Latest Guidebook for Review and Approval Procedures of Overseas

China is one of the fastest growing global economies with one fifth population in the world. Nowadays, China has become the world's second largest healthcare market after the United States.

The Chinese “National Medical Products Administration (NMPA)” and the “National Health Commission (NHC)” jointly issued the latest “Review and Approval Procedures of Overseas Imported New Drugs for Clinical Urgent Demand” on October 23, 2018, which provided a dedicated pathway for priority review and approval of overseas drugs importing to Chinese healthcare market and clarified the specific review and approval procedures.

View Full Report: https://reports.valuates.com/sreport/ACCE-Book-32/Guidebook

Key Highlights:

—A latest description for the China’s changing healthcare market landscape and rapidly changing regulatory framework that let the overseas and multinational pharmaceutical manufacturers clearly understand the present-day realities of the Chinese healthcare market landscape and rapidly changing regulatory framework, and tell the overseas and multinational pharmaceutical manufacturers the opportunities and challenges.
—The latest regulations on priority review and approval procedures of overseas imported new drugs of Chinese clinical urgent demand to smoothly navigate regulatory requirements step by step.
—The scope and selection of drug variety for the priority review and approval procedures of overseas imported new drugs for Chinese clinical urgent demand.
—The detailed Chinese drug regulatory authority's requirements for application materials that the overseas applicants apply for the overseas imported new drugs of Chinese clinical urgent demand. The overseas applicants should prepare the application materials in strict accordance with these requirements.
—The duties and obligations of the overseas applicants on the drugs on the post-marketing in China that are stipulated by the Chinese drug regulatory authority. The overseas applicants must undertake their duties and obligations of their drugs on the post-marketing in China. Otherwise, when the drug on post-marketing has been confirmed to have serious adverse reactions, the Chinese drug regulatory authority will take the emergency control measures to stop sale and use of the drug.
—The detailed Chinese drug regulatory authority's latest “Administrative Measures for Communication and Exchange on Drug Research and Development and Technical Review and Approval” to guide the overseas applicants to take the key first step entry into the dedicated pathway of priority review and approval procedures and to smoothly pass the review and approval procedures.
—A full set of the English and Chinese bilingual application form, materials and minutes template for Communication and Exchange Meeting, which cover the “Application Form of Communication and Exchange Meeting” (annex 1), “The Materials for Communication and Exchange Meeting” (annex 2) and the "Communication and Exchange Meeting Minutes Template" (annex 3) to guide the overseas applicants how to communicate with the Chinese drug regulatory authority.
—The first batch list of overseas imported new drugs for Chinese clinical urgent demand that has been selected by the Chinese drug regulatory authority, which is calling the overseas applicants to submit the application for marketing in China to the Chinese drug regulatory authority, also let the overseas pharmaceutical manufacturers understand the Chinese drug regulatory authority’s distinctive regulatory current status. The list covers 40 drug varieties that have been approved to market in the United States, EU or Japan but that have not been yet marketed in China, and involves with 33 overseas pharmaceutical manufacturers.

Inquire for Sample: https://reports.valuates.com/request/sample/ACCE-Book-32/Guidebook

The audiences of this guidebook are the overseas pharmaceutical manufacturers wishing to enter into the Chinese healthcare market, and the multinational pharmaceutical manufacturers have penetrated into the Chinese healthcare market, as well as their senior executive officers engaging in regulatory affairs expecting to understand the latest regulations on review and approval procedures of overseas imported new drugs for Chinese clinical urgent demand. After having skimmed through this guidebook, audiences can clearly acquire a comprehensive and thorough knowledge of the latest regulations on priority review and approval procedures of overseas imported new drugs for Chinese clinical urgent demand. Access China Management Consulting Ltd hopes this guidebook, based on the full and accurate regulations, can guide the overseas and multinational pharmaceutical manufacturers to achieve a successful entry into the Chinese healthcare market, and smoothly operate their companies in China.

Reasons to Buy:

The Chinese “National Medical Products Administration (NMPA)” and the “National Health Commission (NHC)” jointly issued the latest “Review and Approval Procedures of Overseas Imported New Drugs for Clinical Urgent Demand” on October 23, 2018, which provided a dedicated pathway for priority review and approval of overseas drugs importing to Chinese healthcare market and clarified the specific review and approval procedures. This is a huge business opportunities for the overseas pharmaceutical manufacturers. To capture the huge business opportunities of the Chinese healthcare market and seize a larger part of Chinese healthcare market, how do the foreign pharmaceutical manufacturers in compliance with the latest “Review and Approval Procedures of Overseas Imported New Drugs for Clinical Urgent Demand”? How do the overseas pharmaceutical manufacturers operate business smoothly in China? The overseas and multinational pharmaceutical manufacturers and their senior executive officers engaging in regulatory affairs need a thorough knowledge of the latest regulations for review and approval procedures of overseas imported new drugs for Chinese clinical urgent demand. The Chinese regulatory approach is unique.

The Latest Guidebook for Review and Approval Procedures of Overseas Imported New Drugs for Chinese Clinical Urgent Demand (2019 Edition) is an essential resource for overseas and multinational pharmaceutical manufacturers to successfully acquire the marketing authorization in China, which provided a detailed guidance for comprehensive knowledge of the latest regulations on review and approval procedures of overseas imported new drugs for Chinese clinical urgent demand to navigate regulatory requirements step by step.

Inquire for Discount: https://reports.valuates.com/request/discount/ACCE-Book-32/Guidebook

Our aim is to collate unparalleled Market insights and notify our customers as and when it happens. Valuates is curating premium Market Research Reports from the leading publishers around the globe. We will help you map your information needs to our report repository of Market research reports and guide you through your purchasing decision. We are based out of silicon valley of India (Bengaluru) and provide 24/7 online and offline support to all our customers and just a phone call away.

For Similar Reports:

Access China: https://reports.valuates.com/search?qccode=All&qstr=acce&qcname=All&category=

Valuates Reports
sales@valuates.com
For U.S. Toll Free Call +1 (425) 388-2538
For IST Call +91-8040957137
To know more visit us on:

Website: https://reports.valuates.com/
Linkedin: www.linkedin.com/company/valuatesreports
Facebook: www.facebook.com/valuatesreports
Twitter: www.twitter.com/valuatesreports
Instagram: www.instagram.com/reportsvaluates
Youtube: www.youtube.com/channel/UCH4wNXynaTZbiD5m92WQI4A

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Latest Guidebook for Review and Approval Procedures of Overseas Imported New Drugs for Chinese Clinical Urgent Demand (2019 Edition) here

News-ID: 1755445 • Views: 200

More Releases from Valuates Reports

Global Electric Vehicle (EV) Battery Market Size was Valued At $23 Billion in 20 …
Electric Vehicle Battery Market Statistics - 2025 A battery is used as a secondary power source in automobiles. An electric vehicle (EV) battery is a secondary (rechargeable) battery. It uses chemical energy stored in rechargeable battery packs for power and therefore does not require any combustion engine for propulsion. An electric vehicle battery or traction battery powers the propulsion of battery electric vehicles. In recent years, consumers are more inclined toward battery
3D Cell Culture Market Research Report : Market size, Market Forecast, Market Sh …
The global 3D Cell Culture market is valued at 510 million US$ in 2018 and will reach 1210 million US$ by the end of 2025, growing at a CAGR of 13.1% during 2019-2025. The objectives of this study are to define, segment, and project the size of the 3D Cell Culture market based on company, product type, end user and key regions. A 3D cell culture is an artificially-created environment in
Connected Car Market Report | Market size, Market Forecast, Market Share, Indust …
The Global Connected Car Market was valued at $63,026.0 million in 2017, and is projected to reach $225,158.0 million by 2025, registering a CAGR of 17.1% from 2018 to 2025. In 2017, North America garnered the highest share in the global connected car market. Connected car facilitates connectivity on wheels offering comfort, convenience, performance, safety, and security along with powerful network technology. This enables the driver to connect with online platforms,
Global Aircraft Engine market size will reach 57.28 Billion US$ by 2025, growing …
GLOBAL AIRCRAFT ENGINE MARKET TRENDS: The turbofan segment currently holds a significant share in the demand for aircraft engines and may continue to do so over the forecast period. Turbofan engines are most commonly used in the military and commercial sectors. New aircraft programs such as COMAC C919 and Boeing 777X, which are still in service, are powered by turbofan engines of the latest generation. “The global Aircraft Engine market will reach

All 5 Releases


More Releases for Chinese

Chinese Influence on Global Infrastructure
"The Latest Research Report Chinese Influence on Global Infrastructure provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Chinese Influence Market This report outlines and analyzes all infrastructure projects around the world in which Chinese companies including owners, financers, and contractors are involved. Summary Throughout the 21st century, China has been a world leader in expanding its infrastructure base, creating the worlds largest high-speed rail
Chinese Investors Look Abroad
Beijing, China July 30, 2012 – An Outbound Investment Seminar hosted by Chance & Bridge Partners drew a large audience of investors, Chinese SMEs, and international partner law firms. Many Chinese investors and companies are looking to diversify their holdings and enter new markets. This has led to an increase in cross-border investment, banking, consulting, and legal services for the Chinese clients. Many of these areas were addressed during the
Host1Plus enters Chinese market
London, United Kingdom, January 14, 2011 - Host1Plus, a London based international hosting company has started its operations in Chinese market. The services will be managed from Singapore. Host1Plus has contracted with one of the best data centers in Singapore. This deal allows Host1Plus providing the locally bases services in main language of China. The Chinese support will operate 24/7. The Chinese version of the website is http://cn.host1plus.com in Chinese Simplified
MWM ‒ Chinese Web Site Online
Mannheim, April 26, 2010 In mid-April, a new Web site of MWM GmbH in Chinese went live. However, the new domain with the Internet address mwm.cn is not merely a Chinese translation of the corporate Web site mwm.net. In addition to general information about the Mannheim-based company, the site also features special content elements for the Chinese market. The site contents are also available in English. MWM, a tradition-rich company established
07-13-2009 | Arts & Culture
Yingru.com
About Chinese Calligraphy
Derived from the Greek words for "beauty" and "writing", calligraphy is a very old art. Usually the necessary tools for writing calligraphy are paper, quill and ink. Chinese Calligraphy is based on Chinese characters that are handwritten on paper as well as bones and plates of clay or stone using a brush or a knife (seal carving). In the broader sense calligraphy is a play of brush strokes both, in the
Questrade launches Chinese outreach initiative
Toronto, ON (October 8th, 2008) – Questrade Inc. today announced a new initiative for the Chinese-speaking community. This includes: the Questrade corporate website in traditional and simplified Chinese. The site includes pricing and rates, trading platforms, investment products and services, security and privacy, and contact information. Also available is Questrade’s live help tool, which allows clients to chat instantly online with client services representatives in simplified and traditional Chinese. Edward